Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 469529, 10 pages
http://dx.doi.org/10.1155/2015/469529
Review Article

Vitamin Supplementation as Possible Prophylactic Treatment against Migraine with Aura and Menstrual Migraine

Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

Received 24 December 2014; Accepted 17 February 2015

Academic Editor: Abdel A. Abdel-Rahman

Copyright © 2015 Munvar Miya Shaik and Siew Hua Gan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. IHS, Internation Headache Society Classification—Migraine, 2004, http://ihs-classification.org/en/02_klassifikation/02_teil1/01.00.00_migraine.html.
  2. L. E. Morillo, “Migraine headache,” Clinical Evidence, no. 11, pp. 1696–1719, 2004. View at Google Scholar · View at Scopus
  3. R. B. Lipton, M. E. Bigal, M. Diamond, F. Freitag, M. L. Reed, and W. F. Stewart, “Migraine prevalence, disease burden, and the need for preventive therapy,” Neurology, vol. 68, no. 5, pp. 343–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. “Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society,” Cephalalgia, vol. 8, supplement 7, pp. 1–96, 1988.
  5. IHS Classification ICHD II—Migraine |1|G43, 2004, http://ihs-classification.org/en/02_klassifikation/02_teil1/01.00.00_migraine.html.
  6. World Health Organisation, Headache disorders. Fact Sheet no. 277, 2012, http://www.who.int/mediacentre/factsheets/fs277/en/index.html.
  7. M. Sparaco, M. Feleppa, R. B. Lipton, A. M. Rapoport, and M. E. Bigal, “Mitochondrial dysfunction and migraine: evidence and hypotheses,” Cephalalgia, vol. 26, no. 4, pp. 361–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Montagna, T. Sacquegna, P. Martinelli et al., “Mitochondrial abnormalities in migraine. Preliminary findings,” Headache, vol. 28, no. 7, pp. 477–480, 1988. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Stuart and L. R. Griffiths, “A possible role for mitochondrial dysfunction in migraine,” Molecular Genetics and Genomics, vol. 287, no. 11-12, pp. 837–844, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. Schaefer, R. McFarland, E. L. Blakely et al., “Prevalence of mitochondrial DNA disease in adults,” Annals of Neurology, vol. 63, no. 1, pp. 35–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. H. K. Kim, S. K. Park, J.-L. Zhou et al., “Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain,” Pain, vol. 111, no. 1-2, pp. 116–124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. R. Metea and E. A. Newman, “Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling,” The Journal of Neuroscience, vol. 26, no. 11, pp. 2862–2870, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. A. Leao, “Further observations on the spreading depression of activity in the cerebral cortex,” Journal of Neurophysiology, vol. 10, no. 6, pp. 409–414, 1947. View at Google Scholar
  14. T. Shimomura, A. Kitano, H. Marukawa et al., “Point mutation in platelet mitochondrial tRNA(Leu(UUR)) in patient with cluster headache,” The Lancet, vol. 344, no. 8922, p. 625, 1994. View at Google Scholar · View at Scopus
  15. E. A. Zaki, T. Freilinger, T. Klopstock et al., “Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome,” Cephalalgia, vol. 29, no. 7, pp. 719–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Gupta, R. Pathak, M. S. Bhatia, and B. D. Banerjee, “Comparison of oxidative stress among migraineurs, tension-type headache subjects, and a control group,” Annals of Indian Academy of Neurology, vol. 12, no. 3, pp. 167–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Tuncel, F. I. Tolun, M. Gokce, S. Imrek, and H. Ekerbiçer, “Oxidative stress in migraine with and without aura,” Biological Trace Element Research, vol. 126, no. 1–3, pp. 92–97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Ciancarelli, M. G. Tozzi-Ciancarelli, C. Di Massimo, C. Marini, and A. Carolei, “Urinary nitric oxide metabolites and lipid peroxidation by-products in migraine,” Cephalalgia, vol. 23, no. 1, pp. 39–42, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. X. H. Hu, L. E. Markson, R. B. Lipton, W. F. Stewart, and M. L. Berger, “Burden of migraine in the United States: disability and economic costs,” Archives of Internal Medicine, vol. 159, no. 8, pp. 813–818, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. S. D. Silberstein and W. Edlund, “Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, vol. 55, no. 6, pp. 754–762, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Evers, J. Áfra, A. Frese et al., “EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force,” European Journal of Neurology, vol. 16, no. 9, pp. 968–981, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Antonaci, C. Dumitrache, I. De Cillis, and M. Allena, “A review of current European treatment guidelines for migraine,” The Journal of Headache and Pain, vol. 11, no. 1, pp. 13–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Linde and K. Rossnagel, “Propranolol for migraine prophylaxis,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003225, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Reveiz-Herault, A. F. Cardona, E. G. Ospina, and P. Carrillo, “Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature,” Revista de Neurología, vol. 36, no. 10, pp. 907–912, 2003. View at Google Scholar · View at Scopus
  25. M. Linde, W. M. Mulleners, E. P. Chronicle, and D. C. McCrory, “Topiramate for the prophylaxis of episodic migraine in adults,” The Cochrane Database of Systematic Reviews, vol. 6, Article ID CD010610, 2013. View at Publisher · View at Google Scholar
  26. P. L. Moja, C. Cusi, R. R. Sterzi, and C. Canepari, “Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD002919, 2005. View at Google Scholar · View at Scopus
  27. E. Chronicle and W. Mulleners, “Anticonvulsant drugs for migraine prophylaxis,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD003226, 2004. View at Google Scholar · View at Scopus
  28. S. L. Orr and S. Venkateswaran, “Nutraceuticals in the prophylaxis of pediatric migraine: evidence-based review and recommendations,” Cephalalgia, vol. 34, no. 8, pp. 568–583, 2014. View at Publisher · View at Google Scholar
  29. P. S. Sândor, L. Di Clemente, G. Coppola et al., “Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial,” Neurology, vol. 64, no. 4, pp. 713–715, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Schiapparelli, G. Allais, I. C. Gabellari, S. Rolando, M. G. Terzi, and C. Benedetto, “Non-pharmacological approach to migraine prophylaxis: part II,” Neurological Sciences, vol. 31, supplement 1, pp. S137–S139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Lea, N. Colson, S. Quinlan, J. MacMillan, and L. Griffiths, “The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability,” Pharmacogenetics and Genomics, vol. 19, no. 6, pp. 422–428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Di Rosa, S. Attinà, M. Spanò et al., “Efficacy of folic acid in children with migraine, hyperhomocysteinemia and MTHFR polymorphisms,” Headache, vol. 47, no. 9, pp. 1342–1344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Dalsgaard-Nielsen and J. Trautmann, “Prophylactic treatment of migraine with vitamin B 12,” Ugeskrift for Laeger, vol. 132, no. 7, pp. 339–341, 1970. View at Google Scholar · View at Scopus
  34. A. Bianchi, S. Salomone, F. Caraci, V. Pizza, R. Bernardini, and C. C. D'Amato, “Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis,” Vitamins and Hormones, vol. 69, pp. 297–312, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Menon, R. A. Lea, B. Roy et al., “Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation,” Pharmacogenetics and Genomics, vol. 22, no. 10, pp. 741–749, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Schoenen, J. Jacquy, and M. Lenaerts, “Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial,” Neurology, vol. 50, no. 2, pp. 466–470, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Boehnke, U. Reuter, U. Flach, S. Schuh-Hofer, K. M. Einhäupl, and G. Arnold, “High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre,” European Journal of Neurology, vol. 11, no. 7, pp. 475–477, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Barbiroli, P. Montagna, P. Cortelli et al., “Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura,” Neurology, vol. 42, no. 6, pp. 1209–1214, 1992. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Montagna, P. Cortelli, L. Monari et al., “31P-Magnetic resonance spectroscopy in migraine without aura,” Neurology, vol. 44, no. 4, pp. 666–669, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. W. F. M. Arts, H. R. Scholte, J. M. Bogaard, K. F. Kerrebijn, and I. E. M. Luyt-Houwen, “NADH-CoQ reductase deficient myopathy: successful treatment with riboflavin,” The Lancet, vol. 2, no. 8349, pp. 581–582, 1983. View at Publisher · View at Google Scholar · View at Scopus
  41. N. M. Ramadan, “Prophylactic migraine therapy: mechanisms and evidence,” Current Pain and Headache Reports, vol. 8, no. 2, pp. 91–95, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. G. L. Barkley, N. Tepley, S. Nagel-Leiby, J. E. Moran, R. T. Simkins, and K. M. A. Welch, “Magnetoencephalographic studies of migraine,” Headache, vol. 30, no. 7, pp. 428–434, 1990. View at Publisher · View at Google Scholar · View at Scopus
  43. S. K. Aurora and F. Wilkinson, “The brain is hyperexcitable in migraine,” Cephalalgia, vol. 27, no. 12, pp. 1442–1453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. K. M. A. Welch, S. R. Levine, G. D'Andrea, L. R. Schultz, and J. A. Helpern, “Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy,” Neurology, vol. 39, no. 4, pp. 538–541, 1989. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Maizels, A. Blumenfeld, and R. Burchette, “A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial,” Headache, vol. 44, no. 9, pp. 885–890, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. S. C. MacLennan, F. M. Wade, K. M. L. Forrest, P. D. Ratanayake, E. Fagan, and J. Antony, “High-Dose ribof lavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial,” Journal of Child Neurology, vol. 23, no. 11, pp. 1300–1304, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Condó, A. Posar, A. Arbizzani, and A. Parmeggiani, “Riboflavin prophylaxis in pediatric and adolescent migraine,” The Journal of Headache and Pain, vol. 10, no. 5, pp. 361–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Bruijn, H. Duivenvoorden, J. Passchier, H. Locher, N. Dijkstra, and W.-F. Arts, “Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial,” Cephalalgia, vol. 30, no. 12, pp. 1426–1434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Kutzbach and E. L. R. Stokstad, “Mammalian methylenetetrahydrofolate reductase Partial purification, properties, and inhibition by S-adenosylmethionine,” Biochimica et Biophysica Acta, vol. 250, no. 3, pp. 459–477, 1971. View at Google Scholar · View at Scopus
  50. J. Selhub, “Homocysteine metabolism,” Annual Review of Nutrition, vol. 19, pp. 217–246, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. P. J. Bagley and J. Selhub, “A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 22, pp. 13217–13220, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Jakubowski, “Pathophysiological consequences of homocysteine excess,” The Journal of Nutrition, vol. 136, no. 6, supplement, pp. 1741S–1749S, 2006. View at Google Scholar · View at Scopus
  53. K. S. McCully, “Homocysteine, vitamins, and vascular disease prevention,” The American Journal of Clinical Nutrition, vol. 86, no. 5, pp. 1563S–1568S, 2007. View at Google Scholar · View at Scopus
  54. I. M. Graham and P. O'Callaghan, “Vitamins, homocysteine and cardiovascular risk,” Cardiovascular Drugs and Therapy, vol. 16, no. 5, pp. 383–389, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. S. E. Vollset, H. Refsum, and P. M. Ueland, “Population determinants of homocysteine,” The American Journal of Clinical Nutrition, vol. 73, no. 3, pp. 499–500, 2001. View at Google Scholar · View at Scopus
  56. M. M. Shaik, T. H. Lin, M. A. Kamal, and S. H. Gan, “Do folate, vitamins B6 and B12 play a role in the pathogenesis of migraine? The role of pharmacoepigenomics,” CNS & Neurological Disorders—Drug Targets, vol. 13, no. 5, pp. 828–835, 2014. View at Google Scholar
  57. E. A. MacGregor, “‘Menstrual’ migraine: towards a definition,” Cephalalgia, vol. 16, no. 1, pp. 11–21, 1996. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Salonen and J. Saiers, “Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses,” Cephalalgia, vol. 19, no. 1, pp. 16–19, 1999. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Granella, G. Sances, G. Messa, M. de Marinis, and G. C. Manzoni, “Treatment of menstrual migraine,” Cephalalgia, Supplement, vol. 17, supplement 20, pp. 35–38, 1997. View at Google Scholar · View at Scopus
  60. S. Ziaei, M. Zakeri, and A. Kazemnejad, “A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea,” British Journal of Obstetrics and Gynaecology, vol. 112, no. 4, pp. 466–469, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Ziaei, A. Kazemnejad, and A. Sedighi, “The effect of vitamin E on the treatment of menstrual migraine,” Medical Science Monitor, vol. 15, no. 1, pp. CR16–CR19, 2009. View at Google Scholar · View at Scopus
  62. E. A. MacGregor, “Prevention and treatment of menstrual migraine,” Drugs, vol. 70, no. 14, pp. 1799–1818, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. M. de Mos, F. J. P. M. Huygen, J. P. Dieleman, J. S. H. A. Koopman, B. H. C. Stricker, and M. C. J. M. Sturkenboom, “Medical history and the onset of complex regional pain syndrome (CRPS),” Pain, vol. 139, no. 2, pp. 458–466, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Starr, R. Graepel, J. Keeble et al., “A reactive oxygen species-mediated component in neurogenic vasodilatation,” Cardiovascular Research, vol. 78, no. 1, pp. 139–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Fusayasu, H. Kowa, T. Takeshima, K. Nakaso, and K. Nakashima, “Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods,” Pain, vol. 128, no. 3, pp. 209–214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Wei, W.-W. Li, T.-Z. Guo et al., “Post-junctional facilitation of Substance P signaling in a tibia fracture rat model of complex regional pain syndrome type I,” Pain, vol. 144, no. 3, pp. 278–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. S. J. Padayatty, A. Katz, Y. Wang et al., “Vitamin C as an antioxidant: evaluation of its role in disease prevention,” Journal of the American College of Nutrition, vol. 22, no. 1, pp. 18–35, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. R. S. Perez, P. E. Zollinger, P. U. Dijkstra et al., “Evidence based guidelines for complex regional pain syndrome type 1,” BMC Neurology, vol. 10, article 20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. P. E. Zollinger, W. E. Tuinebreijer, R. W. Kreis, and R. S. Breederveld, “Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial,” The Lancet, vol. 354, no. 9195, pp. 2025–2028, 1999. View at Publisher · View at Google Scholar · View at Scopus
  70. P. E. Zollinger, W. E. Tuinebreijer, R. S. Breederveld, and R. W. Kreis, “Can vitamin C prevent complex regional pain syndrome in patients with wrist fractures? A randomized, controlled, multicenter dose-response study,” The Journal of Bone and Joint Surgery—American Volume, vol. 89, no. 7, pp. 1424–1431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. J.-L. Besse, S. Gadeyne, S. Galand-Desmé, J.-L. Lerat, and B. Moyen, “Effect of vitamin C on prevention of complex regional pain syndrome type I in foot and ankle surgery,” Foot and Ankle Surgery, vol. 15, no. 4, pp. 179–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Chayasirisobhon, “Use of a pine bark extract and antioxidant vitamin combination product as therapy for migraine in patients refractory to pharmacologic medication,” Headache, vol. 46, no. 5, pp. 788–793, 2006. View at Publisher · View at Google Scholar · View at Scopus